CRIS Current Research Information System

ROCCHI, SERENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 3.522
NA - Nord America 2.585
EU - Europa 1.756
AF - Africa 173
SA - Sud America 170
Continente sconosciuto - Info sul continente non disponibili 162
OC - Oceania 9
Totale 8.377
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.505
VN - Vietnam 1.160
CN - Cina 880
SG - Singapore 774
IT - Italia 572
GB - Regno Unito 239
HK - Hong Kong 198
DE - Germania 194
SE - Svezia 145
KR - Corea 144
BR - Brasile 121
IN - India 115
FR - Francia 103
NL - Olanda 102
FI - Finlandia 77
CI - Costa d'Avorio 71
RU - Federazione Russa 69
IE - Irlanda 63
BD - Bangladesh 51
JP - Giappone 47
CA - Canada 41
ZA - Sudafrica 32
SC - Seychelles 30
UA - Ucraina 30
PH - Filippine 27
BG - Bulgaria 26
TG - Togo 24
AT - Austria 23
AR - Argentina 20
MX - Messico 20
ES - Italia 19
BE - Belgio 17
ID - Indonesia 17
EE - Estonia 16
PL - Polonia 16
TH - Thailandia 15
CH - Svizzera 14
TW - Taiwan 14
IQ - Iraq 11
JO - Giordania 11
TR - Turchia 10
EC - Ecuador 8
AU - Australia 7
SA - Arabia Saudita 7
NG - Nigeria 6
IR - Iran 5
JM - Giamaica 5
LT - Lituania 5
MY - Malesia 5
RO - Romania 5
CO - Colombia 4
CZ - Repubblica Ceca 4
DZ - Algeria 4
PK - Pakistan 4
PT - Portogallo 4
PY - Paraguay 4
UZ - Uzbekistan 4
CL - Cile 3
CR - Costa Rica 3
GR - Grecia 3
LB - Libano 3
OM - Oman 3
PE - Perù 3
SV - El Salvador 3
UY - Uruguay 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
CY - Cipro 2
HN - Honduras 2
HU - Ungheria 2
IL - Israele 2
KE - Kenya 2
KZ - Kazakistan 2
LC - Santa Lucia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
TT - Trinidad e Tobago 2
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
EG - Egitto 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
MN - Mongolia 1
MT - Malta 1
NP - Nepal 1
PS - Palestinian Territory 1
SI - Slovenia 1
TN - Tunisia 1
ZM - Zambia 1
Totale 8.216
Salva come PNG Salva come JPEG
Città #
Singapore 559
Ashburn 349
Hefei 312
Ho Chi Minh City 305
Hanoi 243
Chandler 205
Hong Kong 192
Southend 173
Fairfield 159
San Jose 154
Bologna 148
Seoul 141
Beijing 86
Woodbridge 82
Ann Arbor 73
Abidjan 71
Wilmington 71
Seattle 68
Council Bluffs 66
Santa Clara 66
Dong Ket 64
Houston 64
Dublin 63
Helsinki 59
New York 59
Los Angeles 56
Cambridge 50
Dallas 49
Boardman 48
Haiphong 47
Princeton 42
Tokyo 37
Lauterbourg 36
Milan 35
Munich 31
Hyderabad 30
Bengaluru 26
Sofia 25
São Paulo 25
Da Nang 24
Frankfurt am Main 24
Lomé 24
Turin 24
Rome 22
Bremen 21
Buffalo 20
Guangzhou 18
Redondo Beach 18
Biên Hòa 17
Jinan 16
San Diego 16
Westminster 16
Brussels 15
Can Tho 15
Florence 15
Ha Long 15
Shanghai 15
Fabriano 14
Hải Dương 14
London 14
Nuremberg 14
Padova 14
Quận Bình Thạnh 14
Vienna 14
Berlin 13
Falkenstein 13
Redmond 13
Thái Nguyên 13
Jacksonville 12
Jakarta 12
Montreal 12
Nanjing 12
Amman 11
Amsterdam 11
Chicago 11
Phoenix 11
Tongling 11
Warsaw 11
Atlanta 10
Brooklyn 10
Lappeenranta 10
Zhengzhou 10
Điện Bàn 10
Bern 9
Dhaka 9
Nanchang 9
Naples 9
Ninh Bình 9
Quận Một 9
Redwood City 9
San Francisco 9
Shenyang 9
Toronto 9
Bến Tre 8
Changsha 8
Paris 8
Tianjin 8
Turku 8
Wuhan 8
Bắc Giang 7
Totale 5.163
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 719
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 359
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 272
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 251
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 251
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 238
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 238
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 222
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 221
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 218
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 213
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 213
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 213
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 206
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 205
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 205
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 201
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 194
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 192
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 188
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 182
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 181
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 177
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 176
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project 173
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 172
Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy 165
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 160
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 155
Novel insights and therapeutic approaches in secondary AML 150
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 146
Low WT1 Expression Identifies a Subset of Acute Myeloid Leukemia with a Distinct Genotype 138
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 136
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 134
Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma 133
Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors 133
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 131
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 126
Which is the best treatment strategy before autologous peripheral blood stem cell transplantation in POEMS syndrome? 110
Severe SARS-CoV-2 and subsequent fungal infections after CAR T-cell therapy for relapsed/refractory multiple myeloma: a challenging and happy ending fight 102
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 101
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 97
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 92
IMPLEMENTATION OF NEXT GENERATION SEQUENCING AS BEST TOOL FOR ROUTINE EVALUATION OF MINIMAL RESIDUAL DISEASE IN THE DAILY PRACTICE OF MULTIPLE MYELOMA PATIENTS 88
Totale 8.377
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.151
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.151
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022503 0 29 28 49 40 18 15 38 26 66 96 98
2022/2023797 59 100 25 130 55 71 27 44 128 28 84 46
2023/2024382 22 41 24 34 22 87 8 69 6 22 34 13
2024/20251.377 90 135 120 125 110 62 110 40 36 140 144 265
2025/20263.921 435 856 293 330 304 159 310 86 645 242 143 118
2026/2027221 100 121 0 0 0 0 0 0 0 0 0 0
Totale 8.377